Skip to content
HowShorted

Aquestive Therapeutics, Inc. short interest in 2022

In 2022, Aquestive Therapeutics, Inc.'s disclosed short interest ran from 3.24% of shares outstanding on 14 Jan 2022 to 3.22% on 30 Dec 2022, a change of -0.02 percentage points. The year's high was 5.07% on 30 Sep 2022 and its low 1.84% on 31 Aug 2022, averaging 3.26% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.54 days on 30 Nov 2022. Full history: Aquestive Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Aquestive Therapeutics, Inc. in 2022

2022 in figures

Start of year
3.24% (14 Jan 2022)
End of year
3.22% (30 Dec 2022)
Change
-0.02 pp
High
5.07% (30 Sep 2022)
Low
1.84% (31 Aug 2022)
Average
3.26%
Highest days to cover
10.54 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

Aquestive Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20223.24%2.31
31 Jan 20222.68%1.91
15 Feb 20223.50%6.75
28 Feb 20223.30%4.15
15 Mar 20223.19%3.9510-K filed, results (8-K)
31 Mar 20223.06%3.39
14 Apr 20223.23%3.45
29 Apr 20223.20%3.12
13 May 20223.21%2.8710-Q filed, results (8-K)
31 May 20223.57%3.85
15 Jun 20223.25%1.43
30 Jun 20222.51%1.00
15 Jul 20222.19%1.89
29 Jul 20221.97%3.05
15 Aug 20221.96%1.0010-Q filed, results (8-K)
31 Aug 20221.84%1.53
15 Sep 20222.15%2.33
30 Sep 20225.07%1.57
14 Oct 20224.94%5.14
31 Oct 20224.83%9.59
15 Nov 20224.48%6.7710-Q filed, results (8-K)
30 Nov 20224.27%10.54
15 Dec 20223.41%9.33
30 Dec 20223.22%4.85

See also: Aquestive Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.